BMRN Biomarin Pharmaceutical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BMRN

Price (delayed)

$66.7

Market cap

$12.91B

P/E Ratio

175.53

Dividend/share

N/A

EPS

$0.38

Enterprise value

$16.22B

?
Relative Growth: Rel. Growth: 61
Relative Strength: Rel. Strength: 63
Relative Valuation: Rel. Valuation: 17
Relative Profitability: Rel. Profitability: 42

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven ...

Highlights
The revenue has grown by 11% YoY and by 5% from the previous quarter
Biomarin Pharmaceutical's gross profit has increased by 6% YoY and by 4.5% QoQ
BMRN's P/E is 188% above its last 4 quarters average of 60.9 but 2.3% below its 5-year quarterly average of 179.7
The debt has soared by 193% since the previous quarter
Biomarin Pharmaceutical's EPS has shrunk by 89% YoY and by 73% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biomarin.com
Peers: RARE

Key stats

What are the main financial stats of BMRN

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-1.45%
1 week
-0.98%
1 month
12.65%
1 year
14.86%
YTD
12.23%
QTD
16.57%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$3.41B
Gross profit
$2.59B
Operating income
$149.26M
Net income
$72.97M
Gross margin
76.1%
Net margin
2.1%
The net margin has dropped by 90% year-on-year and by 75% since the previous quarter
The net income has dropped by 89% year-on-year and by 73% since the previous quarter
Biomarin Pharmaceutical's operating margin has plunged by 83% YoY and by 55% from the previous quarter
The operating income has dropped by 81% year-on-year and by 53% since the previous quarter

Price vs fundamentals

How does BMRN's price correlate with its fundamentals

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
BMRN P/E details
P/E
175.53
P/B
2.04
P/S
3.79
EV/EBIT
69.71
EV/EBITDA
42.06
EV/Sales
4.76
BMRN's P/E is 188% above its last 4 quarters average of 60.9 but 2.3% below its 5-year quarterly average of 179.7
Biomarin Pharmaceutical's EPS has shrunk by 89% YoY and by 73% QoQ
The stock's price to book (P/B) is 30% less than its 5-year quarterly average of 2.9 but 13% more than its last 4 quarters average of 1.8
The equity has grown by 4.9% YoY
BMRN's price to sales (P/S) is 38% less than its 5-year quarterly average of 6.1 but 11% more than its last 4 quarters average of 3.4
The revenue has grown by 11% YoY and by 5% from the previous quarter

Efficiency

How efficient is Biomarin Pharmaceutical business performance
BMRN's return on assets has dropped by 91% year-on-year and by 76% since the previous quarter
The ROE has plunged by 90% YoY and by 73% from the previous quarter
Biomarin Pharmaceutical's return on sales has shrunk by 76% YoY and by 46% QoQ
Biomarin Pharmaceutical's ROIC has plunged by 75% YoY and by 48% from the previous quarter

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
The total assets is 117% more than the total liabilities
Biomarin Pharmaceutical's total liabilities has soared by 127% from the previous quarter
BMRN's quick ratio has dropped by 77% since the previous quarter and by 65% year-on-year
The debt is 34% smaller than the equity
The debt has soared by 193% since the previous quarter
BMRN's debt to equity has soared by 187% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.